Treatments
EMA
Patients included in the observational cohort received standard thromboprophylaxis with enoxaparin 40 mg od, while patients included in the interventional cohort received subcutaneous enoxaparin in a single daily dose of:60 mg (body weight of 45–60 kg)80 mg (body weight of 61–100 kg)100 mg (body weight > 100 kg)The intermediate dose was chosen to be 1 mg/kg/day which corresponds to half of the recommended enoxaparin therapeutic dose, that is 1 mg/kg twice daily, according to the European Medicines Agency (EMA) technical data sheet of Inhixa [Enoxaparin was to be started on the first day of COVID-19 diagnosis and continued for 14 days, after determination of baseline PT, aPTT, complete blood cell count and creatinine levels. Standard thromboprophylaxis was allowed for a maximum of 72 h before enrollment.